Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew Ku

Showing results (61-70 of 68) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 68 results.
Clinical Lymphoma, Myeloma & Leukemia|September 8, 2021
Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma SubtypesRene-Olivier Casasnovas, George Follows, Josee M Zijlstra, et al.
Journal of Hematology & Oncology|July 17, 2021
Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL studyMarie Maerevoet, Josee M Zijlstra, George Follows, et al.
Future Oncology (London, England)|February 2, 2021
Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphomaJatin Shah, Sharon Shacham, Michael Kauffman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 11, 2026
High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter AnalysisMatthew R Wilson, Katharine L Lewis, Amy A Kirkwood, et al.
Blood|October 13, 2023
The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphomaPietro R Di Ciaccio, Mark N Polizzotto, Kate Cwynarski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 26, 2024
International Prognostic Score for Nodular Lymphocyte-Predominant Hodgkin LymphomaMichael Sargent Binkley, Jamie E Flerlage, Kerry J Savage, et al.
Blood|January 7, 2022
Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patientsMatthew R Wilson, Toby A Eyre, Amy A Kirkwood, et al.
Blood Advances|April 14, 2026
Historical outcomes for patients with stage IA NLPHL: RGlobal nLPHL One Working Group (GLOW) retrospective analysesJamie E Flerlage, Dennis A Eichenauer, Michael Fuchs, et al.
Pageof 7

Showing results (61-70 of 68) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 68 results.
Clinical Lymphoma, Myeloma & Leukemia|September 8, 2021
Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma SubtypesRene-Olivier Casasnovas, George Follows, Josee M Zijlstra, et al.
Journal of Hematology & Oncology|July 17, 2021
Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL studyMarie Maerevoet, Josee M Zijlstra, George Follows, et al.
Future Oncology (London, England)|February 2, 2021
Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphomaJatin Shah, Sharon Shacham, Michael Kauffman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 11, 2026
High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter AnalysisMatthew R Wilson, Katharine L Lewis, Amy A Kirkwood, et al.
Blood|October 13, 2023
The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphomaPietro R Di Ciaccio, Mark N Polizzotto, Kate Cwynarski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 26, 2024
International Prognostic Score for Nodular Lymphocyte-Predominant Hodgkin LymphomaMichael Sargent Binkley, Jamie E Flerlage, Kerry J Savage, et al.
Blood|January 7, 2022
Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patientsMatthew R Wilson, Toby A Eyre, Amy A Kirkwood, et al.
Blood Advances|April 14, 2026
Historical outcomes for patients with stage IA NLPHL: RGlobal nLPHL One Working Group (GLOW) retrospective analysesJamie E Flerlage, Dennis A Eichenauer, Michael Fuchs, et al.
Pageof 7